When are medical apps medical? Off-label use and the Food and Drug Administration

被引:3
作者
Krieger, William H. [1 ]
机构
[1] Univ Rhode Isl, Kingston, RI 02881 USA
来源
DIGITAL HEALTH | 2016年 / 2卷
关键词
Medical apps; Food and Drug Administration; mobile healthcare; off-label; conflict of interest;
D O I
10.1177/2055207616662782
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or 'apps' on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing mobile healthcare sector, the Food and Drug Administration has put forth guidelines to regulate 'mobile medical apps' (MMAs), those health-related apps that are (self) designated as medical devices. In this article, I argue that this decision, to only regulate apps that bill themselves as medical devices, will create a market for 'off-label' app use. Further, I will talk about the oft used analogy between off-label apps and off-label pharmaceuticals, showing that off-labeling apps will provide patients none of the benefits that come with a physician prescribing a drug off-label, while exposing the mobile healthcare consumer to significant risks that go significantly beyond those that we know of (and must accept) from prescription drugs. Recognizing that the Food and Drug Administration is not going to be able to significantly change its policies on oversight, I will suggest specific actions to at least mitigate some of the risks associated with off-label app use.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population
    Chen, H
    Deshpande, AD
    Jiang, R
    Martin, BC
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (09) : 629 - 638
  • [22] Hypoglycemia associated with off-label sitagliptin use
    Whitley, Heather P.
    Kelley, Kristi
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2008, 1 : 3 - 5
  • [23] The use of unlicensed and off-label medicines in the neonate
    Conroy, S
    McIntyre, J
    SEMINARS IN FETAL & NEONATAL MEDICINE, 2005, 10 (02) : 115 - 122
  • [24] Medical-legal aspects of the fungal infection drug therapy in neonatology: evidence-based medicine and off-label prescribing
    Ciuffi, Marta
    Paribello, Francesco
    Demontis, Roberto
    d'Aloja, Ernesto
    Massa, Roberta
    JOURNAL OF PEDIATRIC AND NEONATAL INDIVIDUALIZED MEDICINE, 2014, 3 (02):
  • [25] Off-label use of antipsychotics: are we mad?
    Haw, Camilla
    Stubbs, Jean
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (05) : 533 - 545
  • [26] Medical treatment in infants and young children with epilepsy: Off-label use of antiseizure medications. Survey Report of ILAE Task Force Medical Therapies in Children
    Sourbron, Jo
    Auvin, Stephane
    Arzimanoglou, Alexis
    Cross, J. Helen
    Hartmann, Hans
    Pressler, Ronit
    Riney, Kate
    Sugai, Kenji
    Wilmshurst, Jo M.
    Yozawitz, Elissa
    Lagae, Lieven
    EPILEPSIA OPEN, 2023, 8 (01) : 77 - 89
  • [27] Unlicensed and off-label drug use in a Swiss paediatric university hospital - A pilot study
    Paolo, ER
    Stoetter, H
    Cotting, J
    Frey, P
    Gebri, M
    Beck-Popovic, M
    Tolsa, JF
    Fanconi, S
    Pannatier, A
    SWISS MEDICAL WEEKLY, 2006, 136 (13-14) : 218 - 222
  • [28] Drug utilisation and off-label use of medications in anaesthesia in surgical wards of a teaching hospital
    Patil, Amol E.
    Shetty, Yashashri C.
    Gajbhiye, Snehalata V.
    Salgaonkar, Sweta V.
    INDIAN JOURNAL OF ANAESTHESIA, 2015, 59 (11) : 721 - 727
  • [29] Paediatric drug use with focus on off-label prescriptions at Swedish hospitals - a nationwide study
    Kimland, E.
    Nydert, P.
    Odlind, V.
    Bottiger, Y.
    Lindemalm, S.
    ACTA PAEDIATRICA, 2012, 101 (07) : 772 - 778
  • [30] Supervised off-label prescribing system for enhancing the reporting of adverse drug reactions: example of the CAMTEA system concerning the off-label use of baclofen in alcohol dependence
    Auffret, M.
    Rolland, B.
    Deheul, S.
    Bene, J.
    Danel, T.
    Cottencin, O.
    Bordet, R.
    Gautier, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 44 - 44